Tuesday, October 24, 2023
Genialis, a company specializing in RNA-based biomarkers, has announced a collaborative data-sharing initiative with Cancer Research Horizons (CRH), the innovation division of Cancer Research UK. As part of this partnership, CRH will provide Genialis with anonymized and carefully curated datasets containing 'omics data and clinical information. These datasets will be used to validate Genialis ResponderID™ technology and machine learning-based patient classifiers.
The primary objective of this program is to support the validation of Genialis-developed algorithms across diverse patient populations. This validation process aims to enhance the prediction of patient responses to various therapies, including KRAS inhibitors, immunotherapies, and other emerging therapeutic classes. Collaborative efforts like this are essential in expediting the development of actionable biomarkers for improved patient selection, ensuring that the right treatment reaches the right patient at the right time. Notably, biomarkers can significantly increase the success rate in clinical drug development, potentially up to 12 times, as the clinical failure rate can be as high as 97 percent without them.
CRH, expressed enthusiasm for this collaboration, highlighting the value of Cancer Research UK's extensive and meticulously curated data in supporting tools and products that benefit patients. The availability of detailed colorectal cancer data will play a crucial role in validating Genialis' innovative algorithms for the benefit of patients not only in the UK but globally.
Genialis' ResponderID KRAS, which is rooted in RNA sequencing, is designed to classify patients based on the presence of KRAS mutations. KRAS mutations are prevalent in various common cancer types, including colorectal, lung, and pancreatic cancers. Previous biomarkers developed using Genialis ResponderID technology have demonstrated the ability to predict patient responses to various targeted therapies in solid tumor types, covering a wide range of approved and investigational drugs with different mechanisms of action.
Genialis, emphasized the exciting developments in drug discovery, especially in targeting previously challenging oncogenes like KRAS. He highlighted the opportunity to ensure that these new drugs are directed to the right patients. Access to diverse datasets from UK-based cohorts will enhance the validation process, ensuring the broadest clinical applicability of Genialis' biomarkers. Genialis is excited to have CRH as a trusted global partner.
Genialis is currently participating in the ESMO Congress 2023 in Madrid this week. In the following month, they will be presenting new discoveries related to their biomarker panels and discovery framework at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting & Pre-Conference Programs, scheduled for November 1–5, 2023, in San Diego. To learn more about ResponderID or to schedule an appointment with Genialis.
Source: businesswire.com
